BACKGROUND: Unfractionated heparin is used as the most common anticoagulation for venovenous extracorporeal membrane oxygenation (VV ECMO) patients. However, it is accompanied by frequent bleeding and thrombotic complications. The aim of the study was to demonstrate the feasibility of Enoxaparin anticoagulation for VV ECMO patients. METHODS: This study is a retrospective analysis of VV ECMO patients on continuous intravenous Enoxaparin anticoagulation. The primary outcome was the incidence of bleeding, thrombotic, and neurological complications during ECMO support. The secondary outcome was an analysis of secondary and primary hemostasis profiles. RESULTS: Data from 38 patients were analyzed in this study. The incidence of bleeding complications was 5.3%, for thrombotic complications it was 2.6% and for neurological (bleeding/ischemic events) complications it was 10.5%. The targeted anti-Xa activity of 0.4-0.6 IU/mL was achieved and maintained during whole ECMO period in 28 patients (73.8%), not affecting the hemocoagulation profile represented by APTT-r 1.15 ± 0.2, TT 18.67 ± 3.35 s, PT/INR 1.21 ± 0.19, fibrinogen 5.39 ± 1.49 g/L, antithrombin, and platelet count. Primary hemostasis pathology was diagnosed in all patients by PFA 200 tests Col/EPI 279 ± 38 s and Col/ADP 249 ± 66 s. The running time of ECMO was 7.8 ± 3.4 days. CONCLUSIONS: Enoxaparin anticoagulation appears to be feasible for VV ECMO patients without an increase in adverse events. Further larger-sampled and comparative studies are needed in the future to support our findings.

Department of Anesthesiology and Intensive Care Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Cardiovascular Surgery 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Prague Lung Transplant Program 3rd Department of Surgery 1st Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

McMichael ABV, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022;68(3):303–310. https://doi.org/10.1097/MAT.0000000000001652

Esper SA, Welsby IJ, Subramaniam K, John Wallisch W, Levy JH, Waters JH, et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sang. 2017;112(5):443–452. https://doi.org/10.1111/vox.12514

Kalbhenn J, Schlagenhauf A, Rosenfelder S, Schmutz A, Zieger B. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: rapid onset and fast recovery. J Heart Lung Transplant. 2018;37(8):985–991. https://doi.org/10.1016/j.healun.2018.03.013

Garaj M, Durila M, Vajter J, Solcova M, Marecek F, Hrachovinová I. Extracorporeal membrane oxygenation seems to induce impairment of primary hemostasis pathology as measured by a multiplate analyzer: an observational retrospective study. Artif Organs. 2022;46(5):899–907. https://doi.org/10.1111/aor.14142

Roux E, Bougaran P, Dufourcq P, Couffinhal T. Fluid shear stress sensing by the endothelial layer. Front Physiol. 2020;11:861. https://doi.org/10.3389/fphys.2020.00861

Rana A, Westein E, Niego B, Hagemeyer CE. Shear‐dependent platelet aggregation: mechanisms and therapeutic opportunities. Front Cardiovasc Med. 2019;6:141. https://doi.org/10.3389/fcvm.2019.00141

Gratz J, Pausch A, Schaden E, Baierl A, Jaksch P, Erhart F, et al. Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: a single center experience in 102 lung transplant patients. Artif Organs. 2020;44(6):638–646. https://doi.org/10.1111/aor.13642

Wiegele M, Laxar D, Schaden E, Baierl A, Maleczek M, Knöbl P, et al. Subcutaneous enoxaparin for systemic anticoagulation of COVID‐19 patients during extracorporeal life support. Front Med (Lausanne). 2022;9:879425. https://doi.org/10.3389/fmed.2022.879425

Piwowarczyk P, Szczukocka M, Cios W, Okuńska P, Raszewski G, Borys M, et al. Population pharmacokinetics and probability of target attainment analysis of nadroparin in different stages of COVID‐19. Clin Pharmacokinet. 2023;62(6):835–847. https://doi.org/10.1007/s40262‐023‐01244‐4

Fiamoli V, Blatny J, Zapletal O, Kohlerova S, Janousova E. Treatment of deep vein thrombosis with continuous IV infusion of LMWH: a retrospective study in 32 children. Thrombosis. 2011;2011:981497. https://doi.org/10.1155/2011/981497

Nunez JI, Gosling AF, O'Gara B, Kennedy KF, Rycus P, Abrams D, et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis. Intensive Care Med. 2022;48(2):213–224. https://doi.org/10.1007/s00134‐021‐06593‐x

Kreyer S, Muders T, Theuerkauf N, Spitzhüttl J, Schellhaas T, Schewe JC, et al. Hemorrhage under veno‐venous extracorporeal membrane oxygenation in acute respiratory distress syndrome patients: a retrospective data analysis. J Thorac Dis. 2017;9(12):5017–5029. https://doi.org/10.21037/jtd.2017.11.05

Vaquer S, de Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta‐analysis of complications and mortality of veno‐venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care. 2017;7(1):51. https://doi.org/10.1186/s13613‐017‐0275‐4

Zhang Z, Tang X, Wang R, Li X, Li Y, Tong Z, et al. Application of argatroban in patients receiving extracorporeal membrane oxygenation support: a case‐control study. Zhonghua Wei Zhong Bing ji Jiu Yi Xue. 2022;34(12):1305–1310. https://doi.org/10.3760/cma.j.cn121430‐20220701‐00621

Yasuda N, Goto K, Mizoguchi T, Ohchi Y, Nureki SI, Kitano T. A new anticoagulation strategy using recombinant human thrombomodulin in patients on veno‐venous extracorporeal membrane oxygenation: a retrospective study. Ann Palliat Med. 2021;10(2):1834–1841. https://doi.org/10.21037/apm‐20‐1487

Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, et al. Argatroban versus heparin in patients without heparin‐induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity‐score matched study. Crit Care. 2021;25(1):160. https://doi.org/10.1186/s13054‐021‐03581‐x

Gu Y, Bjelic M, Panda K, Usman AA, Magnuson R, Gosev I. Cannula‐associated deep vein thrombosis after Venovenous extracorporeal membrane oxygenation in patients with and without systemic anticoagulation. J Cardiothorac Vasc Anesth. 2024;38(1):230–236. https://doi.org/10.1053/j.jvca.2023.09.009

Fisser C, Reichenbächer C, Müller T, Schneckenpointner R, Malfertheiner MV, Philipp A, et al. Incidence and risk factors for cannula‐related venous thrombosis after Venovenous extracorporeal membrane oxygenation in adult patients with acute respiratory failure. Crit Care Med. 2019;47(4):e332–e339. https://doi.org/10.1097/CCM.0000000000003650

Lv X, Deng M, Wang L, Dong Y, Chen L, Dai X. Low vs standardized dose anticoagulation regimens for extracorporeal membrane oxygenation: a meta‐analysis. PLoS One. 2021;16(4):e0249854. https://doi.org/10.1371/journal.pone.0249854

Zhao YC, Zhao X, Fu GW, Huang MJ, Li XX, Sun QQ, et al. Heparin‐free after 3000 IU heparin loaded in veno‐venous ECMO supported acute respiratory failure patients with hemorrhage risk: a novel anti‐coagulation strategy. Thromb J. 2022;20(1):36. https://doi.org/10.1186/s12959‐022‐00396‐w

Rivosecchi RM, Arakelians AR, Ryan J, Murray H, Ramanan R, Gomez H, et al. Comparison of anticoagulation strategies in patients requiring Venovenous extracorporeal membrane oxygenation: heparin versus bivalirudin. Crit Care Med. 2021;49(7):1129–1136. https://doi.org/10.1097/CCM.0000000000004944

Sharma SK. Low molecular weight heparins. Med J Armed Forces India. 1998;54(3):285–286. https://doi.org/10.1016/S0377‐1237(17)30571‐3

van de Berg TW, Hulshof AM, Nagy M, van Oerle R, Sels JW, van Bussel B, et al. Suggestions for global coagulation assays for the assessment of COVID‐19 associated hypercoagulability. Thromb Res. 2021;201:84–89. https://doi.org/10.1016/j.thromres.2021.02.026

Willems A, Roeleveld PP, Labarinas S, Cyrus JW, Muszynski JA, Nellis ME, et al. Anti‐Xa versus time‐guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta‐analysis. Perfusion. 2021;36(5):501–512. https://doi.org/10.1177/0267659120952982

Krueger K, Schmutz A, Zieger B, Kalbhenn J. Venovenous extracorporeal membrane oxygenation with prophylactic subcutaneous anticoagulation only: an observational study in more than 60 patients. Artif Organs. 2017;41(2):186–192. https://doi.org/10.1111/aor.12737

Piwowarczyk P, Borys M, Kutnik P, Szczukocka M, Sysiak‐Sławecka J, Szułdrzyński K, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with Venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study. ASAIO J. 2021;67(1):104–111. https://doi.org/10.1097/MAT.0000000000001166

Rychlickova J, Sramek V, Suk P. Use of fondaparinux in patients with heparin‐induced thrombocytopenia on veno‐venous extracorporeal membrane oxygenation: a three‐patient case series report. Front Med (Lausanne). 2023;23(10):1112770. https://doi.org/10.3389/fmed.2023.1112770

van Minnen O, Oude Lansink‐Hartgring A, van den Boogaard B, van den Brule J, Bulpa P, Bunge JJH, et al. Reduced anticoagulation targets in extracorporeal life support (RATE): study protocol for a randomized controlled trial. Trials. 2022;23(1):405. https://doi.org/10.1186/s13063‐022‐06367‐w

Durila M, Vajter J, Garaj M, Smetak T, Hedvicak P, Berousek J, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39(9):980–982. https://doi.org/10.1016/j.healun.2020.05.015

Durila M, Berousek J, Vlasakova V, Vymazal T. Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report. Cardiothorac Surg. 2023;18(1):137. https://doi.org/10.1186/s13019‐023‐02226‐0

Nguyen TP, Phan XT, Nguyen TH, Huynh DQ, Tran LT, Pham HM, et al. Major bleeding in adults undergoing peripheral extracorporeal membrane oxygenation (ECMO): prognosis and predictors. Crit Care Res Prac. 2022;2022:5348835. https://doi.org/10.1155/2022/5348835

Kanji R, Vandenbriele C, Arachchillage DRJ, Price S, Gorog DA. Optimal tests to minimise bleeding and Ischaemic complications in patients on extracorporeal membrane oxygenation. Thromb Haemost. 2022;122(4):480–491. https://doi.org/10.1055/a‐1508‐8230

Anticoagulation Management During ECMO: Narrative Review